Nicht-alkoholische Fettlebererkrankung (NAFLD)

Zusammenfassung

Die nicht-alkoholische Fettlebererkrankung (NAFLD) ist die häufigste chronische Lebererkrankung in Europa und den USA mit steigender Prävalenz. Eine hohe Prävalenz der NAFLD haben insbesondere Risikopatienten mit einem metabolischen Syndrom (Diabetes mellitus Typ 2, Adipositas, Hyperlipdämie). Aus einer blanden Lebersteatose (NAFL) kann sich in 5–20 % der Fälle eine nicht-alkoholische Steatohepatitis (NASH) entwickeln, die zu einer Leberfibrose und -zirrhose fortschreiten kann. Im klinischen Alltag müssen Patienten mit einer NASH oder einer relevanten Fibrosierung identifiziert werden, denn diese Patienten haben eine erhöhte Mortalität im Vergleich zur Normalbevölkerung. Eine etablierte medikamentöse Therapie der NASH steht aktuell nicht zur Verfügung. Deshalb steht die Therapie des metabolischen Syndroms und der Risikofaktoren bei Patienten mit NAFLD im Vordergrund.

Abstract

Non-alcoholic fatty liver disease is the most common chronic liver disease in Europe and in the USA with rising prevalence. Patients with a metabolic syndrome (diabetes mellitus, obesity, dyslipidemia) are patients at risk with the highest prevalence for NAFLD. Progression from a non-alcoholic fatty liver (NAFL) to a non-alcoholic steatohepatitis (NASH) occurs in 5–20 % of patients with the potential to develop a liver fibrosis / cirrhosis. NASH patients and NAFLD patients with higher fibrosis should be identified because they are at risk of a higher mortality. A specific treatment for NASH is not available at the moment. Therefore, the treatment of risk factors and metabolic syndrome has high priority.

Schlüsselwörter

Nicht-alkoholische Fettlebererkrankung (NAFLD) - nicht-alkoholische Fettleber (NAFL) - nicht-alkoholische Fettleberhepatitis (NASH)

Keywords

Non-alcoholic fatty liver disease (NAFLD) - non-alcoholic fatty liver (NAFL) - non-alcoholic steatohepatitis (NASH)

• Literatur

• 1 Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121
• 2 Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231
• 3 Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854
• 4 Angulo P, Kleiner DE, Dam-Larsen S et al. The prognostic relevance of liver histology features in nonalcoholic fatty liver disease: the PRELHIN study. Hepatology 2014; 226A-227A
• 5 Anty R, Marjoux S, Iannelli A et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol 2012; 57: 1090-1096
• 6 Ascha MS, Hanouneh IA, Lopez R et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978
• 7 Assy N, Kaita K, Mymin D et al. Fatty infiltration of liver in hyperlipidemic patients. Dig dis sci 2000; 45: 1929-1934
• 8 Ayonrinde OT, Olynyk JK, Beilin LJ et al. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology 2011; 53: 800-809
• 9 Bataller R, Rombouts K, Altamirano J et al. Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 2011; 25: 231-244
• 10 Bedogni G, Miglioli L, Masutti F et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007; 46: 1387-1391
• 11 Bedossa P, Poitou C, Veyrie N et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012; 56: 1751-1759
• 12 Birerdinc A, Stepanova M, Pawloski L et al. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 35: 76-82
• 13 Blachier M, Leleu H, Peck-Radosavljevic M et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58: 593-608
• 14 Carlsson LM, Peltonen M, Ahlin S et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012; 367: 695-704
• 15 Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 2013; 10: 666-675
• 16 Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023
• 17 Chen HP, Shieh JJ, Chang CC et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013; 62: 606-615
• 18 Dunn W, Sanyal AJ, Brunt EM et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 2012; 57: 384-391
• 19 Ekstedt M, Franzen LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873
• 20 Ekstedt M, Hagstrom H, Nasr P et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547-1554
• 21 Gaia S, Carenzi S, Barilli AL et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 2011; 54: 64-71
• 22 Geier A. Shedding new light on vitamin D and fatty liver disease. J Hepatol 2011; 55: 273-275
• 23 Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance?. J Obes 2013; 2013: 839 275
• 24 Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321
• 25 Koehler EM, Schouten JN, Hansen BE et al. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol 2012; 57: 1305-1311
• 26 Kowdley KV, Belt P, Wilson LA et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012; 55: 77-85
• 27 Krawczyk M, Portincasa P, Lammert F. PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease. Semin Liver Dis 2013; 33: 369-379
• 28 Kwok R, Tse YK, Wong GL et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 2014; 39: 254-269
• 29 Leite NC, Salles GF, Araujo AL et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009; 29: 113-119
• 30 Masarone M, Federico A, Abenavoli L et al. Non alcoholic Fatty liver: epidemiology and natural history. Rev Recent Clin Trials 2014; 9: 126-133
• 31 Merriman RB, Ferrell LD, Patti MG et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44: 874-880
• 32 Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385: 956-965
• 33 Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci 2014; 15: 8591-8638
• 34 Promrat K, Kleiner DE, Niemeier HM et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-129
• 35 Sanyal AJ, Banas C, Sargeant C et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43: 682-689
• 36 Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685
• 37 Schauer PR, Bhatt DL, Kirwan JP et al. Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med 2014; 370: 2002-2013
• 38 Suzuki A, Angulo P, Lymp J et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 2005; 41: 64-71
• 39 Targher G, Bertolini L, Scala L et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutrition, metabolism, and cardiovascular diseases. NMCD 2007; 17: 517-524
• 40 Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285
• 41 Weiss J, Rau M, Geier A. Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int 2014; 111: 447-452
• 42 Weiss JRM, Bantel H, Bock H et al. Erste Daten zur Versorgungssituation von Patienten mit nicht alkoholischer Fettlebererkrankung (NAFLD) in Deutschland – Eine Umfrage an universitären hepatologischen Zentren. Z Gastroenterol 2015; in press
• 43 Whalley S, Puvanachandra P, Desai A et al. Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clin Med 2007; 7: 119-124
• 44 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10: 1342-1359 e1342
• 45 Wong VW, Wong GL, Yeung DK et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol 2015; 62: 182-189
• 46 Younossi ZM, Reyes MJ, Mishra A et al. Systematic review with meta-analysis: non-alcoholic steatohepatitis – a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014; 39: 3-14
• 47 Zhang H, Gao C, Fang L et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol 2013; 48: 78-87